Friday, 3rd December Melbourne Immunotherapy Network Winter Symposium 2021
Registration Opens
12:00PM - 1:30PM
Friday, 3rd December
Cuzens Pre Function foyer
Session 1 - Autoimmunity/IAEs
1:30PM - 3:10PM
Friday, 3rd December
Kooringa-Kitchener rooms
Chair: Cynthia Louis
- Type I interferon in SLE - from therapeutic target to therapy - Eric Morand
- CTLA4-Ig therapies and cell surface CTLA4 engage the PDL1:PD1 immune checkpoint - Ross Dickins
- Can we tame the immune response to treat gastric cancer without adverse outcomes? - Lorraine O'Reilly
- Gut microbiota influence cancer immunotherapy outcomes - Miles Andrews
- Milestones to a cure: a path to uncovering HLA-C*06:02 restricted antigen triggers in psoriasis - Asolina Braun
- Understanding rheumatic toxicities of immune checkpoint inhibitors - Cynthia Louis
Afternoon Tea
3:10PM - 3:40PM
Friday, 3rd December
Keppel-Maryland-Cumberland rooms
Session 2 - Cancer immunotherapy
3:40PM - 5:30PM
Friday, 3rd December
Kooringa-Kitchener rooms
Chair: Paul Beavis
Sponsored by:
- Improved therapeutic vaccines to enhance the clinical benefit of cancer immunotherapy - Riccardo Dolcetti
- Presentation abstract/description : “CAR T-cells for AML: Roadblocks and work-arounds” - Katherine Cummins
- Regulation of stemness and exhaustion of CD8+ T cells during chronic infection - Axel Kallies
- New approaches for refuelling” CAR T cell therapy for the effective treatment of cancer - Phil Darcy
- Combination approaches to enhance the effect of cellular immunotherapy in prostate cancer: when all else fails - Gail Risbridger
- Next Generation Armoured CAR T Cells for the Treatment of Solid Tumours - Imran G House
- Deciphering mechanisms of anti-tumoral CD4+ T cells and the role of MHC class II in melanoma immunosurveillance. - Emma Bawden
- Predicting outcome for combination immunotherapy in patients with rare cancers. - Andreas Behren
Posters, Trade Display & Drinks
5:30PM - 7:30PM
Friday, 3rd December
Keppel-Maryland-Cumberland rooms
- Novel EGFRvIII-specific murine CAR T cells completely eliminate glioblastoma tumours - Rebecca C Abbott
- In Vitro Suppression of T Cell Proliferation Is a Conserved Function of Primary and Immortalized Human Cancer-Associated Fibroblasts - Mohammed MA Abuwarwar
- Selective expansion of CCR6-Vdelta2+Vgamma9+ T-cells following treatment with phosphoantigens or bisphosphonates in pigtail macaques (Macaca nemestrina) - Isaac M Barber-Axthelm
- Using CRISPR/Cas9 to engineer next-generation armoured CAR T cells with improved efficacy against solid tumours - Amanda X. Y. Chen
- miR-21 promotes breast cancer metastasis via immunosuppressive and immune-independent mechanisms - Lap Hing Chi
- Novel diagnostic and prognostic biomarkers in prostate cancer - Jessica Da Gama Duarte
- CRISPR-Mediated PTPN2 Deletion in CAR T Cells Enhances Anti-Tumour Efficacy - Xin Du
- Programming Vγ2Vδ2 T cells for improved immunotherapeutic outcomes - Kirsty R Field
- The ratio of exhausted to resident infiltrating lymphocytes is prognostic for colorectal cancer (CRC) patient outcome - Momeneh Foroutan
- HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma induced apoptosis - Andrew J Freeman
- Therapeutic restoration of suppressed tumour-intrinsic type I IFN signalling in bone-metastatic breast cancer - Miriam Fuentes-Guirado
- Ovarian carcinosarcoma engrafted in NSG MHCnull mice as a pre-clinical patient derived xenograft (PDX) model to explore personalised T-cell receptor therapy - Gwo Ho
- Dual-specific chimeric antigen receptor T cells eliminate heterogeneous tumours - Misty R Jenkins
- The role of the short chain fatty acid butyrate in CD4+ T cell immunity - Ariane Lee
- Characterisation of the differential systemic immune response for stable versus progressive metastatic breast cancer using single-cell genetics - Stefano Mangiola
- Targeting immunosuppressive myeloid cells to improve immunotherapy for breast cancer - Kellie Mouchemore
- Targeting Tuft cells and Innate Lymphoid Cells in Gastric Cancer - Ryan N O'Keefe
- Pomalidomide as an immunomodulatory agent to enhance NK cell anti-HIV immunity - Rachel D Pascoe
- Myc as the master regulator of dormancy in triple negative breast cancer - Charlotte C Roelofs
- Immunostaging for melanoma to to accurately predict risk of relapse in stage III melanoma patients - Elnaz Tavancheh
- Use of a novel transgenic mouse to investigate adenosine receptor A2AR expression on immune subsets within tumours following immunotherapy - Kirsten L Todd
- PTPN2 elicits cell autonomous and non-cell autonomous effects on anti-tumour immunity in triple negative breast cancer - Mara Zeissig
- Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in tumour-free mice: consequences for fertility of female cancer survivors - Lauren R Alesi
- Decreasing Destiny – The role of PD-1 in T cell activation - Melissa Butler
- Checkpoint inhibitor immunotherapy cause ovarian dysfunction in tumour bearing mice: consequences for fertility of female cancer survivors - Amy L Winship
- A Highly Conserved CD28 Transmembrane Motif Drives CAR-induced Cytokine Secretion - Nicholas Chandler
- Improving safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies - Ashleigh Davey
- Targeting PTP1B to enhance CAR T cell-mediated anti-tumour immunity - Florian Wiede
Conference Dinner
7:30PM - 10:00PM
Friday, 3rd December
Radius Restaurant